This document discusses various classes of antiviral drugs and examples within each class. It covers:
1) Agents for treating herpes simplex virus and varicella zoster virus like acyclovir which require phosphorylation to become activated.
2) Agents for treating cytomegalovirus like ganciclovir which is activated similarly to acyclovir but has different pharmacokinetics.
3) Antiretroviral agents used to treat HIV/AIDS that target different stages of the viral lifecycle such as reverse transcriptase inhibitors and protease inhibitors.
pharmacology of Antiviral Agents final.pptNorhanKhaled15
Viral replication consists of several steps that can be targeted by antiviral agents. Acyclovir and related drugs like valacyclovir and famciclovir inhibit herpes virus replication through phosphorylation within infected cells and inhibition of viral DNA polymerase. Foscarnet inhibits viral DNA and RNA polymerases without requiring phosphorylation. Ganciclovir and cidofovir also inhibit viral polymerases after intracellular phosphorylation. Antiretroviral drugs used to treat HIV include nucleoside analog reverse transcriptase inhibitors like zidovudine, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors which inhibit viral enzymes and replication at different stages of the viral life cycle.
Herpes viruses are associated with diseases like cold sores and genital infections. There are several drugs that are effective against these viruses during acute infection, including acyclovir, cidofovir, foscarnet, ganciclovir, penciclovir/famciclovir, and trifluridine. These drugs work by incorporating into viral DNA or inhibiting viral polymerases. Highly active antiretroviral therapy (HAART) uses combinations of drugs from five classes to suppress HIV replication, including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, entry inhibitors, and integra
I have tried to provide an outline regarding the general antivirals available in our country..and discussed regarding MOA,indications and Therapeutic uses.
This document outlines a lecture on antiviral drugs for various viral infections. It begins with learning objectives about classifying antiviral drugs and their mechanisms and clinical applications. It then covers drugs for anti-herpes therapy like acyclovir and valacyclovir; anti-HIV drugs like NRTIs, NNRTIs, and protease inhibitors; drugs for hepatitis B and C like lamivudine, entecavir, and interferon; and drugs for influenza like oseltamivir and zanamivir. The document discusses the mechanisms, uses, dosing, and adverse effects of these various antiviral agents.
This document discusses antiviral agents for nonretrovirals. It begins by outlining the key learning objectives which are to describe viral infections, classification of antiviral agents, their mechanisms of action and resistance. It then classifies antiviral agents into non-retroviral and antiretroviral categories. Under non-retroviral agents, it describes treatments for influenza, herpes and hepatitis viruses. It provides details on specific drugs for each virus type, including their mechanisms of action, resistance and pharmacokinetics.
This document summarizes various anti-viral and anti-fungal agents. It discusses the mechanism of action and clinical uses of nucleoside reverse transcriptase inhibitors like zidovudine, didanosine, lamivudine, emtricitabine and others for treating HIV. It also covers anti-herpes drugs like acyclovir, valacyclovir, famciclovir and penciclovir; anti-CMV drugs like ganciclovir and cidofovir; and other agents for treating hepatitis, influenza and fungal infections. The adverse effects and pharmacokinetics of many of these drugs are also summarized.
This document summarizes various anti-viral and anti-fungal agents. It discusses the mechanism of action and clinical uses of nucleoside reverse transcriptase inhibitors like zidovudine, didanosine, lamivudine, emtricitabine and others for treating HIV. It also covers anti-herpes drugs like acyclovir, valacyclovir, famciclovir and penciclovir; anti-CMV drugs like ganciclovir and cidofovir; and other agents for treating hepatitis, influenza and fungal infections. The adverse effects, pharmacokinetics and mechanisms of these different classes of drugs are summarized.
This document discusses various antiviral drugs that target different stages of the viral lifecycle. It describes the mechanism of action, pharmacokinetics, uses, and side effects of several nucleoside analogues (acyclovir, cidofovir, famciclovir, ganciclovir), nucleotide analogues (foscarnet, ribavirin), and antisense oligonucleotides (fomivirsen) used to treat infections caused by DNA and RNA viruses like herpesviruses, influenza, hepatitis, and cytomegalovirus. The drugs inhibit viral DNA or RNA synthesis through competitive inhibition or chain termination mechanisms. Many require activation by viral or host kinases to form active triphosphate
pharmacology of Antiviral Agents final.pptNorhanKhaled15
Viral replication consists of several steps that can be targeted by antiviral agents. Acyclovir and related drugs like valacyclovir and famciclovir inhibit herpes virus replication through phosphorylation within infected cells and inhibition of viral DNA polymerase. Foscarnet inhibits viral DNA and RNA polymerases without requiring phosphorylation. Ganciclovir and cidofovir also inhibit viral polymerases after intracellular phosphorylation. Antiretroviral drugs used to treat HIV include nucleoside analog reverse transcriptase inhibitors like zidovudine, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors which inhibit viral enzymes and replication at different stages of the viral life cycle.
Herpes viruses are associated with diseases like cold sores and genital infections. There are several drugs that are effective against these viruses during acute infection, including acyclovir, cidofovir, foscarnet, ganciclovir, penciclovir/famciclovir, and trifluridine. These drugs work by incorporating into viral DNA or inhibiting viral polymerases. Highly active antiretroviral therapy (HAART) uses combinations of drugs from five classes to suppress HIV replication, including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, entry inhibitors, and integra
I have tried to provide an outline regarding the general antivirals available in our country..and discussed regarding MOA,indications and Therapeutic uses.
This document outlines a lecture on antiviral drugs for various viral infections. It begins with learning objectives about classifying antiviral drugs and their mechanisms and clinical applications. It then covers drugs for anti-herpes therapy like acyclovir and valacyclovir; anti-HIV drugs like NRTIs, NNRTIs, and protease inhibitors; drugs for hepatitis B and C like lamivudine, entecavir, and interferon; and drugs for influenza like oseltamivir and zanamivir. The document discusses the mechanisms, uses, dosing, and adverse effects of these various antiviral agents.
This document discusses antiviral agents for nonretrovirals. It begins by outlining the key learning objectives which are to describe viral infections, classification of antiviral agents, their mechanisms of action and resistance. It then classifies antiviral agents into non-retroviral and antiretroviral categories. Under non-retroviral agents, it describes treatments for influenza, herpes and hepatitis viruses. It provides details on specific drugs for each virus type, including their mechanisms of action, resistance and pharmacokinetics.
This document summarizes various anti-viral and anti-fungal agents. It discusses the mechanism of action and clinical uses of nucleoside reverse transcriptase inhibitors like zidovudine, didanosine, lamivudine, emtricitabine and others for treating HIV. It also covers anti-herpes drugs like acyclovir, valacyclovir, famciclovir and penciclovir; anti-CMV drugs like ganciclovir and cidofovir; and other agents for treating hepatitis, influenza and fungal infections. The adverse effects and pharmacokinetics of many of these drugs are also summarized.
This document summarizes various anti-viral and anti-fungal agents. It discusses the mechanism of action and clinical uses of nucleoside reverse transcriptase inhibitors like zidovudine, didanosine, lamivudine, emtricitabine and others for treating HIV. It also covers anti-herpes drugs like acyclovir, valacyclovir, famciclovir and penciclovir; anti-CMV drugs like ganciclovir and cidofovir; and other agents for treating hepatitis, influenza and fungal infections. The adverse effects, pharmacokinetics and mechanisms of these different classes of drugs are summarized.
This document discusses various antiviral drugs that target different stages of the viral lifecycle. It describes the mechanism of action, pharmacokinetics, uses, and side effects of several nucleoside analogues (acyclovir, cidofovir, famciclovir, ganciclovir), nucleotide analogues (foscarnet, ribavirin), and antisense oligonucleotides (fomivirsen) used to treat infections caused by DNA and RNA viruses like herpesviruses, influenza, hepatitis, and cytomegalovirus. The drugs inhibit viral DNA or RNA synthesis through competitive inhibition or chain termination mechanisms. Many require activation by viral or host kinases to form active triphosphate
Antiviral drugs are a class of medications used to treat viral infections by inhibiting the replication or growth of viruses in the body. These drugs work by targeting specific components of a virus, such as the viral enzymes, proteins, or nucleic acids, and disrupting their ability to infect or replicate inside host cells. This can help reduce the severity of symptoms, prevent complications, and speed up recovery.
There are many types of antiviral drugs available, including:
1. Nucleoside or nucleotide analogues: These drugs mimic the structure of the nucleosides or nucleotides needed for viral replication, thereby interfering with virus replication.
2. Protease inhibitors: These drugs block the activity of viral proteases, which are enzymes that are required for the replication and assembly of some viruses.
3. Interferons: These drugs are naturally occurring proteins that help the immune system fight viral infections by boosting the body's antiviral response.
4. Neuraminidase inhibitors: These drugs block the activity of viral neuraminidase, an enzyme that is required for the release of virus particles from infected cells.
5. Fusion inhibitors: These drugs block the fusion of viral and host cell membranes, which is an essential step in viral entry and replication.
Antiviral drugs can be used to treat a variety of viral infections, including influenza, HIV/AIDS, hepatitis B and C, herpes, and Ebola. However, the effectiveness of these drugs can vary depending on the specific virus and the stage of infection. Antiviral drugs may also have side effects, and it is important to consult with a healthcare provider before taking them.
Pharmacology and therapeutics of Antiretroviral agentPrajwalGhatol1
Title: Antiretroviral Agents Pharmacology
Introduction:
Antiretroviral agents play a crucial role in the management of human immunodeficiency virus (HIV) infections. HIV is a retrovirus that attacks the immune system, specifically the CD4 cells (T cells), leading to a weakened immune system and increased susceptibility to various infections. Antiretroviral therapy (ART) aims to suppress viral replication, maintain or restore immune function, and improve overall quality of life. This note provides a detailed overview of the pharmacology of antiretroviral agents.
Classification of Antiretroviral Agents:
Antiretroviral agents are classified into several classes based on their mechanism of action:
a. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs):
- Examples: Zidovudine, Lamivudine, Tenofovir.
- Mechanism: They inhibit reverse transcriptase, an enzyme essential for viral DNA synthesis, by acting as faulty substrates.
b. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):
- Examples: Efavirenz, Nevirapine, Rilpivirine.
- Mechanism: They bind directly to reverse transcriptase, causing conformational changes that inhibit its activity.
c. Protease Inhibitors (PIs):
- Examples: Atazanavir, Darunavir, Ritonavir.
- Mechanism: PIs interfere with the protease enzyme, hindering the cleavage of viral polyproteins and preventing the maturation of infectious viral particles.
d. Integrase Strand Transfer Inhibitors (INSTIs):
- Examples: Raltegravir, Elvitegravir, Dolutegravir.
- Mechanism: INSTIs block the integrase enzyme, preventing the integration of viral DNA into the host genome.
e. Entry Inhibitors:
- Examples: Enfuvirtide, Maraviroc.
- Mechanism: Enfuvirtide inhibits the fusion of viral and cellular membranes, while Maraviroc blocks the CCR5 receptor, preventing viral entry into the cell.
Pharmacokinetics:
a. Absorption:
Antiretroviral drugs can be taken orally, and their absorption may be affected by food. For instance, some PIs are better absorbed with food, while others should be taken on an empty stomach.
b. Distribution:
Antiretrovirals distribute widely in the body, including the central nervous system. Some drugs have specific formulations to enhance their penetration into sanctuary sites.
c. Metabolism:
Many antiretrovirals undergo hepatic metabolism, primarily through the cytochrome P450 system. Drug interactions may occur, influencing the metabolism of co-administered medications.
d. Excretion:
Renal excretion is a significant route for some antiretrovirals. Dosing adjustments are necessary in patients with renal impairment.
Resistance:
a. Mechanisms:
HIV has a high mutation rate, leading to the emergence of drug-resistant strains. Resistance can result from mutations in the viral genome, reducing drug binding or increasing the efficiency of viral replication.
b. Prevention:
Combination therapy, or highly active antiretroviral therapy (HAART), is employed to reduce the risk of resistance. This involves using
The document discusses various antiviral drugs, classifying them based on their mechanism of action and the stage of the viral life cycle they target. It describes several nucleoside analog drugs like acyclovir, gancyclovir, vidarabine, idoxuridine and trifluridine which inhibit viral DNA polymerase after being phosphorylated. It also discusses mechanisms, spectra, pharmacokinetics and uses of specific antiviral drugs like amantadine, ribavirin, and protease inhibitors.
Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit its development.
Viruses are the smallest infectious agents consisting of genetic material surrounded by a protein coat. They cannot reproduce on their own and must infect a host cell. There are DNA and RNA viruses that cause various diseases. Antiviral drugs target different stages of the viral life cycle, including entry, replication, assembly and release. Examples discussed include nucleoside/non-nucleoside reverse transcriptase inhibitors for HIV, and amantadine/oseltamivir for influenza which interfere with viral uncoating and neuraminidase activity respectively. Interferons are endogenous proteins with broad-spectrum antiviral effects. Acyclovir targets herpes viruses by incorporating into viral DNA. Effective antiviral treatment requires combinations of drugs to prevent
The document discusses various antiviral drugs, classifying them based on their mechanism of action and site of inhibition in the viral life cycle. It summarizes several representative antiviral drugs, including their chemistry, mechanism of action, antiviral spectrum, pharmacokinetics, administration, adverse effects and therapeutic uses. Key drugs discussed include amantadine, ribavirin, acyclovir, gancyclovir, vidarabine, idoxuridine and trifluridine.
This document discusses antiviral drugs used to treat retrovirus infections such as HIV. It classifies antiretroviral drugs into different categories based on their mechanism of action, including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, CCR5 receptor inhibitors, and integrase inhibitors. Key drugs from each category are described in terms of their pharmacological properties and clinical applications. The principles of highly active antiretroviral therapy and guidelines for HIV treatment and prevention are also summarized.
Antiviral drugs can be classified into several groups based on their mechanism of action and target virus. Anti-herpes drugs like acyclovir work by inhibiting viral DNA polymerase. Anti-retroviral drugs target HIV and include nucleoside reverse transcriptase inhibitors like AZT, non-nucleoside reverse transcriptase inhibitors like nevirapine, and protease inhibitors like ritonavir. These anti-HIV drugs are most effective when used in combination to suppress viral replication and improve immune function in patients. Common side effects of many antiviral drugs include bone marrow suppression, gastrointestinal issues, and peripheral neuropathy.
This document discusses antiviral drugs used to treat viral infections. It begins with an introduction to viruses and their parasitism of host cells. The history of antiviral development is covered from the 1960s onwards. Viruses are classified and several antiviral drug classes are described including anti-herpes drugs like acyclovir and famciclovir, anti-retrovirals for HIV like zidovudine and lamivudine, and the non-selective antiviral interferon. Specific viruses and the doses, mechanisms, and adverse effects of antiviral treatments are outlined. The document concludes with a discussion of herpes virus classification and post-exposure prophylaxis for preventing HIV infection.
anti virals -medication used against viral actionTeena42750
This document discusses antiviral drugs and classifies them based on their mechanism of action and target viruses. It describes several classes of antiviral drugs including anti-herpes drugs like acyclovir and famciclovir, anti-influenza drugs like oseltamivir and zanamivir, and various classes of antiretroviral drugs used to treat HIV like nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors. Each drug is discussed in terms of its mechanism of action, target virus, uses, and common side effects.
The document discusses anti-viral drugs, their mechanisms of action, spectra, pharmacokinetics and therapeutic uses. It describes how certain drugs like acyclovir are selectively activated within virus infected cells. Common classes include purine/pyrimidine analogs which inhibit viral DNA polymerase, and prodrugs requiring phosphorylation. Anti-virals inhibit active viral replication but do not eliminate non-replicating virus. Effective treatment depends on inhibitory drug concentrations at infection sites.
The document discusses several antiviral and antifungal agents, their mechanisms of action, clinical uses, and side effects. It covers agents that target herpes viruses like acyclovir and famciclovir, cytomegalovirus like ganciclovir and cidofovir, and influenza like amantadine and rimantadine. The agents work by inhibiting viral entry, replication, or incorporation into viral DNA. They are used to treat herpes, CMV, influenza and other viral infections. Common side effects include gastrointestinal issues, renal toxicity, and myelosuppression.
The document discusses several antiviral and antifungal agents, their mechanisms of action, clinical uses, and side effects. It covers agents that target herpes viruses like acyclovir and famciclovir, cytomegalovirus like ganciclovir and cidofovir, and influenza like amantadine and rimantadine. The agents work by inhibiting viral entry, replication, or incorporation into viral DNA. They are used to treat herpes, CMV, influenza and other viral infections. Common side effects include gastrointestinal issues, renal toxicity, and myelosuppression.
This document discusses antiviral drugs used to treat various viral infections. It describes the classification of antiviral drugs, including drugs for herpes viruses like acyclovir and ganciclovir; influenza viruses like amantadine and zanamivir; hepatitis viruses like interferon and lamivudine; HIV like reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors. It provides details on the mechanisms of action, clinical uses, pharmacokinetics, and adverse effects of representative drugs in each class.
Most antiviral drugs target viral replication by interfering with viral nucleic acid synthesis or late protein synthesis. They require conversion to active triphosphate forms by host cell kinases to inhibit viral polymerases more selectively than host polymerases. Combination antiviral therapy increases effectiveness and delays drug resistance emergence. Current HIV treatment involves two or three drugs before symptoms, often two reverse transcriptase inhibitors plus a protease inhibitor to slow viral load increases and delay resistance.
Most antiviral drugs target viral replication by interfering with viral nucleic acid synthesis or late protein synthesis. They require conversion to active triphosphate forms by host cell kinases to inhibit viral polymerases more selectively than host polymerases. Combination antiviral therapy increases effectiveness and delays drug resistance emergence. Current HIV treatment involves two or three drugs before symptoms, often two reverse transcriptase inhibitors plus a protease inhibitor to slow viral load increases and delay resistance.
This document summarizes different types of antiviral drugs. It discusses the stages of viral replication and how different antiviral drugs act at various steps in the viral life cycle. It covers drugs used to treat viruses like HIV, hepatitis B and C viruses, herpes viruses, influenza viruses, and more. The mechanisms of action, uses, and common side effects of different classes of antivirals like protease inhibitors, reverse transcriptase inhibitors, integrase inhibitors, and entry/fusion inhibitors are summarized.
This document provides information on various antiviral agents used to treat different viral infections:
1. Acyclovir and valacyclovir are effective against HSV and VZV. They require phosphorylation inside infected cells to inhibit viral DNA synthesis. Famciclovir and penciclovir are prodrugs of active metabolites that also inhibit HSV and VZV.
2. Ganciclovir, valganciclovir and cidofovir are effective against CMV. They require phosphorylation for activation and inhibition of viral DNA polymerase.
3. Amantadine and rimantadine inhibit influenza A by preventing viral uncoating. They are effective for prevention but
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPRAHUL
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
Antiviral drugs are a class of medications used to treat viral infections by inhibiting the replication or growth of viruses in the body. These drugs work by targeting specific components of a virus, such as the viral enzymes, proteins, or nucleic acids, and disrupting their ability to infect or replicate inside host cells. This can help reduce the severity of symptoms, prevent complications, and speed up recovery.
There are many types of antiviral drugs available, including:
1. Nucleoside or nucleotide analogues: These drugs mimic the structure of the nucleosides or nucleotides needed for viral replication, thereby interfering with virus replication.
2. Protease inhibitors: These drugs block the activity of viral proteases, which are enzymes that are required for the replication and assembly of some viruses.
3. Interferons: These drugs are naturally occurring proteins that help the immune system fight viral infections by boosting the body's antiviral response.
4. Neuraminidase inhibitors: These drugs block the activity of viral neuraminidase, an enzyme that is required for the release of virus particles from infected cells.
5. Fusion inhibitors: These drugs block the fusion of viral and host cell membranes, which is an essential step in viral entry and replication.
Antiviral drugs can be used to treat a variety of viral infections, including influenza, HIV/AIDS, hepatitis B and C, herpes, and Ebola. However, the effectiveness of these drugs can vary depending on the specific virus and the stage of infection. Antiviral drugs may also have side effects, and it is important to consult with a healthcare provider before taking them.
Pharmacology and therapeutics of Antiretroviral agentPrajwalGhatol1
Title: Antiretroviral Agents Pharmacology
Introduction:
Antiretroviral agents play a crucial role in the management of human immunodeficiency virus (HIV) infections. HIV is a retrovirus that attacks the immune system, specifically the CD4 cells (T cells), leading to a weakened immune system and increased susceptibility to various infections. Antiretroviral therapy (ART) aims to suppress viral replication, maintain or restore immune function, and improve overall quality of life. This note provides a detailed overview of the pharmacology of antiretroviral agents.
Classification of Antiretroviral Agents:
Antiretroviral agents are classified into several classes based on their mechanism of action:
a. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs):
- Examples: Zidovudine, Lamivudine, Tenofovir.
- Mechanism: They inhibit reverse transcriptase, an enzyme essential for viral DNA synthesis, by acting as faulty substrates.
b. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):
- Examples: Efavirenz, Nevirapine, Rilpivirine.
- Mechanism: They bind directly to reverse transcriptase, causing conformational changes that inhibit its activity.
c. Protease Inhibitors (PIs):
- Examples: Atazanavir, Darunavir, Ritonavir.
- Mechanism: PIs interfere with the protease enzyme, hindering the cleavage of viral polyproteins and preventing the maturation of infectious viral particles.
d. Integrase Strand Transfer Inhibitors (INSTIs):
- Examples: Raltegravir, Elvitegravir, Dolutegravir.
- Mechanism: INSTIs block the integrase enzyme, preventing the integration of viral DNA into the host genome.
e. Entry Inhibitors:
- Examples: Enfuvirtide, Maraviroc.
- Mechanism: Enfuvirtide inhibits the fusion of viral and cellular membranes, while Maraviroc blocks the CCR5 receptor, preventing viral entry into the cell.
Pharmacokinetics:
a. Absorption:
Antiretroviral drugs can be taken orally, and their absorption may be affected by food. For instance, some PIs are better absorbed with food, while others should be taken on an empty stomach.
b. Distribution:
Antiretrovirals distribute widely in the body, including the central nervous system. Some drugs have specific formulations to enhance their penetration into sanctuary sites.
c. Metabolism:
Many antiretrovirals undergo hepatic metabolism, primarily through the cytochrome P450 system. Drug interactions may occur, influencing the metabolism of co-administered medications.
d. Excretion:
Renal excretion is a significant route for some antiretrovirals. Dosing adjustments are necessary in patients with renal impairment.
Resistance:
a. Mechanisms:
HIV has a high mutation rate, leading to the emergence of drug-resistant strains. Resistance can result from mutations in the viral genome, reducing drug binding or increasing the efficiency of viral replication.
b. Prevention:
Combination therapy, or highly active antiretroviral therapy (HAART), is employed to reduce the risk of resistance. This involves using
The document discusses various antiviral drugs, classifying them based on their mechanism of action and the stage of the viral life cycle they target. It describes several nucleoside analog drugs like acyclovir, gancyclovir, vidarabine, idoxuridine and trifluridine which inhibit viral DNA polymerase after being phosphorylated. It also discusses mechanisms, spectra, pharmacokinetics and uses of specific antiviral drugs like amantadine, ribavirin, and protease inhibitors.
Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit its development.
Viruses are the smallest infectious agents consisting of genetic material surrounded by a protein coat. They cannot reproduce on their own and must infect a host cell. There are DNA and RNA viruses that cause various diseases. Antiviral drugs target different stages of the viral life cycle, including entry, replication, assembly and release. Examples discussed include nucleoside/non-nucleoside reverse transcriptase inhibitors for HIV, and amantadine/oseltamivir for influenza which interfere with viral uncoating and neuraminidase activity respectively. Interferons are endogenous proteins with broad-spectrum antiviral effects. Acyclovir targets herpes viruses by incorporating into viral DNA. Effective antiviral treatment requires combinations of drugs to prevent
The document discusses various antiviral drugs, classifying them based on their mechanism of action and site of inhibition in the viral life cycle. It summarizes several representative antiviral drugs, including their chemistry, mechanism of action, antiviral spectrum, pharmacokinetics, administration, adverse effects and therapeutic uses. Key drugs discussed include amantadine, ribavirin, acyclovir, gancyclovir, vidarabine, idoxuridine and trifluridine.
This document discusses antiviral drugs used to treat retrovirus infections such as HIV. It classifies antiretroviral drugs into different categories based on their mechanism of action, including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, CCR5 receptor inhibitors, and integrase inhibitors. Key drugs from each category are described in terms of their pharmacological properties and clinical applications. The principles of highly active antiretroviral therapy and guidelines for HIV treatment and prevention are also summarized.
Antiviral drugs can be classified into several groups based on their mechanism of action and target virus. Anti-herpes drugs like acyclovir work by inhibiting viral DNA polymerase. Anti-retroviral drugs target HIV and include nucleoside reverse transcriptase inhibitors like AZT, non-nucleoside reverse transcriptase inhibitors like nevirapine, and protease inhibitors like ritonavir. These anti-HIV drugs are most effective when used in combination to suppress viral replication and improve immune function in patients. Common side effects of many antiviral drugs include bone marrow suppression, gastrointestinal issues, and peripheral neuropathy.
This document discusses antiviral drugs used to treat viral infections. It begins with an introduction to viruses and their parasitism of host cells. The history of antiviral development is covered from the 1960s onwards. Viruses are classified and several antiviral drug classes are described including anti-herpes drugs like acyclovir and famciclovir, anti-retrovirals for HIV like zidovudine and lamivudine, and the non-selective antiviral interferon. Specific viruses and the doses, mechanisms, and adverse effects of antiviral treatments are outlined. The document concludes with a discussion of herpes virus classification and post-exposure prophylaxis for preventing HIV infection.
anti virals -medication used against viral actionTeena42750
This document discusses antiviral drugs and classifies them based on their mechanism of action and target viruses. It describes several classes of antiviral drugs including anti-herpes drugs like acyclovir and famciclovir, anti-influenza drugs like oseltamivir and zanamivir, and various classes of antiretroviral drugs used to treat HIV like nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors. Each drug is discussed in terms of its mechanism of action, target virus, uses, and common side effects.
The document discusses anti-viral drugs, their mechanisms of action, spectra, pharmacokinetics and therapeutic uses. It describes how certain drugs like acyclovir are selectively activated within virus infected cells. Common classes include purine/pyrimidine analogs which inhibit viral DNA polymerase, and prodrugs requiring phosphorylation. Anti-virals inhibit active viral replication but do not eliminate non-replicating virus. Effective treatment depends on inhibitory drug concentrations at infection sites.
The document discusses several antiviral and antifungal agents, their mechanisms of action, clinical uses, and side effects. It covers agents that target herpes viruses like acyclovir and famciclovir, cytomegalovirus like ganciclovir and cidofovir, and influenza like amantadine and rimantadine. The agents work by inhibiting viral entry, replication, or incorporation into viral DNA. They are used to treat herpes, CMV, influenza and other viral infections. Common side effects include gastrointestinal issues, renal toxicity, and myelosuppression.
The document discusses several antiviral and antifungal agents, their mechanisms of action, clinical uses, and side effects. It covers agents that target herpes viruses like acyclovir and famciclovir, cytomegalovirus like ganciclovir and cidofovir, and influenza like amantadine and rimantadine. The agents work by inhibiting viral entry, replication, or incorporation into viral DNA. They are used to treat herpes, CMV, influenza and other viral infections. Common side effects include gastrointestinal issues, renal toxicity, and myelosuppression.
This document discusses antiviral drugs used to treat various viral infections. It describes the classification of antiviral drugs, including drugs for herpes viruses like acyclovir and ganciclovir; influenza viruses like amantadine and zanamivir; hepatitis viruses like interferon and lamivudine; HIV like reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors. It provides details on the mechanisms of action, clinical uses, pharmacokinetics, and adverse effects of representative drugs in each class.
Most antiviral drugs target viral replication by interfering with viral nucleic acid synthesis or late protein synthesis. They require conversion to active triphosphate forms by host cell kinases to inhibit viral polymerases more selectively than host polymerases. Combination antiviral therapy increases effectiveness and delays drug resistance emergence. Current HIV treatment involves two or three drugs before symptoms, often two reverse transcriptase inhibitors plus a protease inhibitor to slow viral load increases and delay resistance.
Most antiviral drugs target viral replication by interfering with viral nucleic acid synthesis or late protein synthesis. They require conversion to active triphosphate forms by host cell kinases to inhibit viral polymerases more selectively than host polymerases. Combination antiviral therapy increases effectiveness and delays drug resistance emergence. Current HIV treatment involves two or three drugs before symptoms, often two reverse transcriptase inhibitors plus a protease inhibitor to slow viral load increases and delay resistance.
This document summarizes different types of antiviral drugs. It discusses the stages of viral replication and how different antiviral drugs act at various steps in the viral life cycle. It covers drugs used to treat viruses like HIV, hepatitis B and C viruses, herpes viruses, influenza viruses, and more. The mechanisms of action, uses, and common side effects of different classes of antivirals like protease inhibitors, reverse transcriptase inhibitors, integrase inhibitors, and entry/fusion inhibitors are summarized.
This document provides information on various antiviral agents used to treat different viral infections:
1. Acyclovir and valacyclovir are effective against HSV and VZV. They require phosphorylation inside infected cells to inhibit viral DNA synthesis. Famciclovir and penciclovir are prodrugs of active metabolites that also inhibit HSV and VZV.
2. Ganciclovir, valganciclovir and cidofovir are effective against CMV. They require phosphorylation for activation and inhibition of viral DNA polymerase.
3. Amantadine and rimantadine inhibit influenza A by preventing viral uncoating. They are effective for prevention but
Similar to Antiviral_Drugs.(Third_year) (1).pptx (20)
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPRAHUL
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
Walmart Business+ and Spark Good for Nonprofits.pdfTechSoup
"Learn about all the ways Walmart supports nonprofit organizations.
You will hear from Liz Willett, the Head of Nonprofits, and hear about what Walmart is doing to help nonprofits, including Walmart Business and Spark Good. Walmart Business+ is a new offer for nonprofits that offers discounts and also streamlines nonprofits order and expense tracking, saving time and money.
The webinar may also give some examples on how nonprofits can best leverage Walmart Business+.
The event will cover the following::
Walmart Business + (https://business.walmart.com/plus) is a new shopping experience for nonprofits, schools, and local business customers that connects an exclusive online shopping experience to stores. Benefits include free delivery and shipping, a 'Spend Analytics” feature, special discounts, deals and tax-exempt shopping.
Special TechSoup offer for a free 180 days membership, and up to $150 in discounts on eligible orders.
Spark Good (walmart.com/sparkgood) is a charitable platform that enables nonprofits to receive donations directly from customers and associates.
Answers about how you can do more with Walmart!"
Executive Directors Chat Leveraging AI for Diversity, Equity, and InclusionTechSoup
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...PECB
Denis is a dynamic and results-driven Chief Information Officer (CIO) with a distinguished career spanning information systems analysis and technical project management. With a proven track record of spearheading the design and delivery of cutting-edge Information Management solutions, he has consistently elevated business operations, streamlined reporting functions, and maximized process efficiency.
Certified as an ISO/IEC 27001: Information Security Management Systems (ISMS) Lead Implementer, Data Protection Officer, and Cyber Risks Analyst, Denis brings a heightened focus on data security, privacy, and cyber resilience to every endeavor.
His expertise extends across a diverse spectrum of reporting, database, and web development applications, underpinned by an exceptional grasp of data storage and virtualization technologies. His proficiency in application testing, database administration, and data cleansing ensures seamless execution of complex projects.
What sets Denis apart is his comprehensive understanding of Business and Systems Analysis technologies, honed through involvement in all phases of the Software Development Lifecycle (SDLC). From meticulous requirements gathering to precise analysis, innovative design, rigorous development, thorough testing, and successful implementation, he has consistently delivered exceptional results.
Throughout his career, he has taken on multifaceted roles, from leading technical project management teams to owning solutions that drive operational excellence. His conscientious and proactive approach is unwavering, whether he is working independently or collaboratively within a team. His ability to connect with colleagues on a personal level underscores his commitment to fostering a harmonious and productive workplace environment.
Date: May 29, 2024
Tags: Information Security, ISO/IEC 27001, ISO/IEC 42001, Artificial Intelligence, GDPR
-------------------------------------------------------------------------------
Find out more about ISO training and certification services
Training: ISO/IEC 27001 Information Security Management System - EN | PECB
ISO/IEC 42001 Artificial Intelligence Management System - EN | PECB
General Data Protection Regulation (GDPR) - Training Courses - EN | PECB
Webinars: https://pecb.com/webinars
Article: https://pecb.com/article
-------------------------------------------------------------------------------
For more information about PECB:
Website: https://pecb.com/
LinkedIn: https://www.linkedin.com/company/pecb/
Facebook: https://www.facebook.com/PECBInternational/
Slideshare: http://www.slideshare.net/PECBCERTIFICATION
2. Classification of Antiviral Drugs
• Best Classification Based on 1) Type of Viral
Infections (Organisms) or 2) its site:
• I. Agents to Treat Herpes Simplex virus (HSV) and
Varicella Zoster Virus (VZV) infections.
• II. Agents To Treat Cytomegalovirus infection (CMV)
• III. Drugs Used for Rx of AIDS (Antiretroviral Agents)
• IV. Antihepatitis Agents
• V. Antiviral Used for Respiratory Tract Infections:
3. ANTIVIRAL DRUGS: GENERAL FEATURES
- Many antiviral drugs are purine or pyrimidine analogs.
-Many antiviral drugs are prodrugs.
They must be phosphorylated by viral or cellular enzymes in order to
become active.
- Antiviral drugs typically have a restricted spectrum of antiviral activity
and inhibit a specific viral protein, most often an enzyme involved in
viral nucleic acid synthesis.
- Single nucleotide changes leading to critical amino acid substitutions in
a target protein often are sufficient to cause antiviral drug resistance.
- Current agents inhibit active replication but do not eliminate
nonreplicating or latent viruses so that viral growth may resume after
drug removal. Effective host immune response remain essential for
recovery from infection.
4. - Antiviral drugs may have antiviral synergistic effects when given
concomitantly (i.e. gancyclovir and foscarnet, zidovudine and
didanosine, zidovudine and protease inhibitors, etc.). In other cases
toxic synergistic effects preclude concurrent administration of two
antiviral drugs (i.e. zidovudine and acyclovir, zidovudine and
gancyclovir, etc.)
- Clinical efficacy of antiviral drugs depends on achieving
inhibitory concentrations within infected cells. Therefore a clear
relationship between blood concentration and clinical response
have not been established for most antiviral agents.
8. 1) Agents to Treat Herpes Simplex virus (HSV)
and Varicella Zoster Virus (VZV) infections.
• Examples: Acyclovir (prototype); Valcyclovir;
Famiciclovir; Trifluridine (Topical)
• MOA: (49-2) They are guanosine analogs
without sugar moiety (so what?).
• Three phosphorylation Steps are required for
activation (one depends on viral thymidine
kinase), forming triphosphate form (1 in the viral
2 on the host). This (acyclo-GTP), will
incorporate into viral DNA-causing premature
DNA-chain termination (irreversible binding to
viral DNA polymerase) and inhibition of DNA
snythesis.
• What is the effect of drugs on the host cells
(not infected)?
14. • Resistance: Can be developed due to
deficient or alteration of thymidine kinase
and or alteration DNA polymerases.
• Cross resistance: to valcyclovir,
famiciclovir and gancyclovir
• but no cross resistance for cidofovir
(Cytomegalovirus drug)? Why (see Fig 49-2)
15. PK of Acyclovir :
–is available as oral (15-20%) (not affected by food),
topical and i.v.
–Does it have high or low oral bioavailability?
–Short t1l2 3 hr (thus given 4-5 times daily) and
eliminated mainly by kidney (t1l2 prolonged in renal
impairment) t1l2 20 hr.
–Distribute in ALL parts of the body, including CNS
(e.g: encephalitis) .
–What is Valacyclovir?.
–What is the meaning of a prodrug?
Clinical Uses (see Table 49-1)
HSV, Varicella-zoster VZV; Epstein-Barr virus mediated
infection; HSV encephalitis; Genital herpes infection.
16.
17. Side Effects of Acyclovir
(Generally speaking, acyclovir considers to be
save drug Why?, however, it may produce:
1 . Transient Renal dysfunction at high dose or at i.v (Crystalline
Nephropathy). RX
2. GIT disturbances
How valcyclovir differs from acyclovir?
High oral bioavailability; long duration (almost five times the
plasma concentration)
Can replace i.v cyclivir
Effective even for CMV
Side Effects: Thrombotic thrombocytopenic purpura in pts
with AIDS
18. PHARMACOLOGY OF IDOXURIDINE AND TRIFLURIDINE
Chemistry
-Idoxuridine and trifluridine are pyrimidine nucleoside analogs.
Mechanism of action
-The drugs are converted by cellular enzymes to their triphosphate analogs
which inhibits viral (and, to a lesser extent, human) DNA synthesis.
Antiviral spectrum and resistance
-Antiviral spectrum includes HSV-1, HSV-2 and VZV.
-Prolonged treatment can select drug-resistant mutants.
Administration
-topically administered (eye, oral, genital mucosae)
Adverse effects
-Pain, pruritus, edema involving the eye or lids.
-Allergic reactions (rare)
Therapeutic uses
-Ocular, oral, genital HSV infections
19. PHARMACOLOGY OF FOSCARNET
Chemistry
-Foscarnet is an inorganic pyrophosphate analog
Mechanism of action
-The drug directly inhibits viral DNA-polymerase and viral inverse
transcriptase (it does not require phosphorylation for antiviral
activity)
Antiviral spectrum and resistance
-Antiviral spectrum of foscarnet includes HSV-1, HSV-2, VZV,
CMV and HIV.
-Resistance may be due to altered viral DNA polymerase
-Cross-resistance between foscarnet and other antiviral drugs is very
rare.
20. Pharmacokinetics and administration
-F(oral): 10-20%
-Distribution in all body tissues including CNS (CSF/plasma ratio » 0.7)
-Renal excretion: > 80%
-Half life: 3-4 days
-Administration: IV
Adverse effects
-Hypocalcemia and hypomagnesemia (due to chelation of the drug with
divalent cations) are common.
-Neurotoxicity (headache, tremor, irritability, hallucinations, seizures)
-Nephrotoxicity (acute tubular nephrosis, interstitial nephritis)
Therapeutic uses
Foscarnet is an alternative drug for
-HSV infections (due to thymidine kinase deficient strains which are
acyclovir resistant)
-HSV infections in immunocompromised patient
-CMV retinitis (gancyclovir resistant)
-CMV infections in immunocompromised patient
21. Other drugs for HSV and VSV infections
Penciclovir
−Undergoes activation by viral thymidine kinase and the
triphosphate form inhibits DNA polymerase but doesnot
cause chain termination
Famciclovir
−Is a prodrug converted to penciclovir by first-pass
metabolism in the liver.
−It is well tolerated and similar to acyclovir in its PK
Docosanol
−An aliphatic alcohol that inhibits fusion between the
HSV envelope and plasma membranes. Prevents viral
entry. Topical
25. • II. Agents To Treat Cytomegalovirus infection (CMV)
• Ganciclovir: Analog of acyclovir
• Why Acyclovir is not active against CMV?
• MOA: Similar to acyclovir
• PK: How does it differ from acyclovir?
– What is valganciclovir?
Clinical Uses of Ganciclovir:
i.v: (commonly used formulation)
- to delay the progression of CMV retinitis in patients with
AIDS 2 weeks followed by oral form)
- for CMV colitis, esophagitis and pneumonitis.
- to prevent CMV before trasplantation.
Oral: (Used for prophylaxis)
- CMC prophylaxis in transplant patients
- prevention of end organ CMV disease in AIDS patients.
- as maintenance therapy for CMV retinitis.
Intraocularly (implant):
Rx CMV retinitis.
26. Adverse Effects of Ganciclovir:
- Myelosuppression (neurtroprnia 20-30%) and increases
if given with? Zidovudine; azathioprime, mycophenolate
mofetil)
- Vitreous hemorrhage and retinal detachment with
intraocular implant.
- Mitogenicity in mammalian cells and
- carcinogenic in animals at high dose
What is valganciclovir and when it should be
used?
Simply it is an oral replacement for i.V
Ganciclovir.
27.
28. • Cidofovir:
– Differs from acyclovir in its long t1/2 26 hr with active
metabolite.and MOA.
– Activity: CMV; HSV; VZV and in:
– MOA: phosophorylation does not depend on viral
enzyme, and works as inhibitor and alternative
substrate for viral DNA polymerase.
– Used for CMV retinitis, colitis, and esophagitis.
and for Acyclovir-resistant
PK: produce active metabolite, thus it has long t1/2,
eliminated in the kidney, Probenicid prolongs its action.
but with poor CNS penetration.
Why acyclivor is better than Cidofovir for encephalitis?
Side effects: Dose-dependent nephrotoxicity (53%) and
uveitis and decrease IOP
29. • Note: Normally, RNA from DNA,
however,
• Reverse transcriptase = RNA-directed
DNA polymerase (DNA polymerase that
transcribes single- stranded RNA into
double-stranded DNA.
30. • III. Drugs Used for Rx of AIDS (Antiretroviral
Agents)
– AIDS are caused by HIV, and zidovudine was the first drug used
(1987).
– To understand drugs used for AIDS, the life cycle of HIV should
be utilized for drugs combination (See Figure 38-16)
– Drug combination or the so-called Highly Active Antiretriviral
Therapy (HAART) (Figure 38-17) as well as adherence to the
regimen, both are very essential.
Classification of Anti AIDS (Based on life cycle)
Table 2 and Figure 38-17):
1) Nucleotide Reverse Transcriptase Inhibitors (NRTIS)
e.g.;Zidovudine
2) Non Nucleotide Reverse Transcriptase Inhibitors (NNRTIS)
e.g.; Efavirenz
3) Protease Inhibitors e.g. Saquinavir; Ritonavir; Indinavir
4) Viral Fusion Inhibitor e.g. Enfuvirtide
31. • Objectives of HIV Treatment:
– Suppression of viral replication (decrease the
viral load).
– Restoration of a degree of
immunocompetency to the host.
– Decrease incidence of opportunistic
infections.
– prolonged survival
32. Replicative cycle of HIV-1, an example of a retrovirus, showing the sites
of action of antiviral agents.
Various antiviral agents are shown in blue. Key: RT, reverse
transcriptase; cDNA, complementary DNA; mRNA, messenger RNA; Tat, a
protein that regulates viral transcription and affects the rate of
replication; RNaseH, ribonuclease H; gp120, envelope glycoprotein.
43. 1) Nucleotide Reverse Transcriptase Inhibitors
(NRTIS)
Chemistry (Figure 49-4): These are analogs of native
ribosides (nucleotide with side chain containing
ribose) but lack the 3’-hydroxy group.
MOA: Similar to most antiviral drugs, require
triphosphorylation but mainly by cellular enzyme.
Competitive inhibitor of HIV-1 reverse transcriptase.
The triphosphorylated analog (with no hydroxyl
group) incorporate into viral DNA by virus RT,
preventing DNA chain elongation (See Figure 38-
16)
NRTIS can be classified into group A (thymidine
Analoges) (Zidovudine and Stavudine) and group
B: (Didanosin; Zalcitabine and Lamovidin)
46. Zidovudine (AZT): 3-azido3deoxythymidine (AZT) (Pyrimidine
Analog) Important Discovery 1987 G
MOA: Requires mammalian thymidine kinase for triphophorylation.
Resistance: Due to high rate of mutation at several code.
• PK:
– Excellent oral absorption
– Penetrate well to CNS but has short t1/2
.(3 hrs 100 mg q 5 hr)
– Metabolized by liver to glucuronated AZT but eliminated by kidney,
therefore:
Its half life is affected in uremic and hepatic patients and by drugs that
metabolized by glucoronidation. E.g.
Uses:
-The most important drug in HAART.
- for Rx and prevention of neanate (transmission) 14-35 of gestation
and i.v during labor then AZT syrup from birth till 6 weeks.(decrease
vertical transmission).
Does it decrease the severity of infection in mother?
Adverse effects:
- Pronounced bone marrow suppression as severe anemia &
leucopenia (increases if given with?); thrombocytopenia .
- Headache, insomnia & seizure at higher doses.
47. • Stavudine:
– This is like AZT, a thymidine analogue
(activated by the same enzymes) therefore,
should not be combined with AZT
– Like AZT has good oral bioavailability
– Eliminated mainly by tubular secretion and
glomerular filtration.
– Major Side effect: sensory neuropathy and
Hyperlipedemia but no leucopenia
Note: MCQ on side effect of Stavudine specially
that related to neuropathy.
48. Tenofovir:
• (it has one phospahate group in its
structure) therefore requires only two
phosphorylation
• Has long t1/2 (once daily)
• Similar to AZT requires dose adjustment in
renal impairment.
• Unlike AZT has no myelosuppressive
effect.
49. • Didanosine (dideoxyinosine) With out the two hydroxyl group.
– Differ from Zidovudine:
• Low oral bioavailability and destroy by acid (given before meals),
but they change to chewable Tablets.
• Used for AZT resistance.
• Like AZT, Its elimination is dependent on kidney.
• However, It is a chelating agent (interaction with tetracyclins and
fluroquinoline (Two hour should be given before or after).
Side Effects:
• Pancreatitis (check serum amylase) increases in alcoholics
• Peripheral neuropathy (Dose related); hepatitis, but unlike AZT has
no leucopenia.
• Optic neuritis
• Hyperuricemia
Note: should not be combined with AZT! Antagonize each other.
• Zalcitabine:
– Similar to Didanosine
50. • Lamivudine:
– This cytosine analog is the most interesting anti viral
drug, because it can be used for HIV and HBV
infections.
Advantages:
- Like AZT has good oral bioavailability with active
metabolite.Safest drug among NRTI
- Can be combined with AZT
COMBIVIR (Lamovidine 150 mg + Zidovudine 300 mg)
- No significant side effects because it does not affect
mitochondrial DNA synthesis or bone marrow
precursor cells
Disadvantages:
has high rate of mutation if given alone, therefore
should be combined in case of AIDS and hepatitis).
Is there any differences in the dose of Lamivudine for
HIV and HBV patients?
51. • Zalcitabine (dideoxycytidine ddc)
– Does it remind you with Didanosine?
This drug used as replacement for Lamivudine
in HIV, but differ in the following:
1) Oral bioavailability is dependent on food
(Why?)
2) Similar to didanosine, it produces dose
dependent neuropathy due to inhibition of
mammalian mitochondrial DNA
polymerases.
3) Pancreatitis but less than didanosine.
52. Emtricitabine:
This is fluoro-derivative of Lamuvidine; can
replaced the former in HBV and HIV pateints.
Which of the following drugs does not cause peripheral
neuropathy?
a) Lamivudine
b) Stavudine
c) Didanosine
d) Zalcitabine
53. 2) Non Nucleotide Reverse Transcriptase Inhibitors
(NNRTIS) e.g.;Nevirapine; Efaverenz
MOA: Bind selectively and non-competitive way to HIV
reverse transcriptase at a side adjacent to that of
NRTIs, and from their names they are neither
nucleotide triphosphate nor require phosphorylation to
be active.
Resistance:
Rapid resistance can be developed but it is not cross
resistance to NRTIs or protease inhibitor.
Main features:
These drugs are lipophilic in nature with high degree
of protein binding and oral bioavailability. Also, some
of them either inhibit or enhance the liver metabolic
enzymes.
Hypersensitivity has been observed with their use as
serous rashes and Steves-Johnson syndrome. LFT
54. • Nevirapine:
PK:
Lipophilic drug with high oral bioavailability.(not food dependent)
Metabolized by liver and it is enzyme inducer, may decrease the t1/2 of
some drugs including anti AIDS, contraceptives and warfarin.
Uses:
In AIDS, it is only used together with other antiretrovirals.
Single dose (200 mg) for transmission of HIV from mother to
newborn
A single dose of nevirapine to the mother, with or without a dose of nevirapine to the infant, added to
oral zidovudine prophylaxis starting at 28 weeks' gestation, is highly effective in reducing mother-to-
child transmission of HIV. N Engl J Med. 2004 Jul 15;351(3):217-28. Epub 2004 Jul 9
Disadvantages;
Life threatening skin rashes including Stevens-Johnson Syndrome and
toxic epidermal necrolysis (can be reduced by Starting with low dose).
Fulminant hepatitis
Delaviridine:
It is unlike nevirapine, it inhibits CYP3A, with rash but not to the
degree of Stavens Johnson Syndrome.
55. • Efaverenz (commonly used NNRTI Safest):
Drug with long t1/2 (40-55 hrs) with high albumin
binding; metabolized in the liver with some
enzyme induction.
Side Effects: Occur only in the beginning of
therapy, mainly in CNS (agitation, delusion;
nightmares; euphoria)
Note: Unlike, nevirapine, efaverenz should not
be used in pregnancy (fetal abnormalities)
Note: Enzyme inhibitors and inducers affects ALL
NNRTI to the same level.
56.
57.
58. • HIV Protease Inhibitors:
• Very good Discovery 1995, make significant Decline
– MOA:
• Reversible inhibitors of the HIV aspartyl protease
• What is aspartyl protease?
• Are these drugs specific for HIV protease as
compared to human? (Thousand)
– PK:
• In contrast to NNRTIs, most protease inhibitors
have poor oral bioavailability and affected by by
meal.
• All are metabolized in the liver CYP3A4 isozyme of
Cyto P450, and some of them like Ritonavir is
CYP3A4 inhibitor.
• High protein binding and pass blood BB.
59. • What is the pharmacokinetic enhancer?
Drug Interaction: Pharmacokinetic Type
Since they are inhibitors of CYP isozyme
(Ritonavir (strong) while Saquinavir is the least)
Drug interaction so common e.g: Statins;
Benzodiazepines; Fentanyl; warfarin; phenytion
Side Effects:
• Common: Parasthesias, N/V and Diarrhea.
Hyperglycemia, Hypertriglyeridemia, LDL.
Chronic use gives rise to Buflo hump and breast
enlargement.(Similar to steriods but
60. Ritonavir
– Is not uesd alone as a single protease inhibitorm but it is used as
pharmacokinetic enhancer.
– Side effects: GIT; paresthesia; hypertriglycemia; elevated AST
• Indinavir:
– Well absorbed orally with lowest protein binding among this
group and high penetration to the CNS; but should be given in
empty stomach.
– Enzyme inhibitor
– It is given together with Ritonavir as Trade name
Side Effects:
- Indirect hyperbilirubinemia,thrombocytopenia and
nephrolithiasis due to crystallization of the drug (good hydration).
Fat disribution.
• Lopinavir/Ritonavir (Common and prefered
combination)
– Here, Ritonavir is used to suppress CYP3A4 .
– What are the drugs that decrease the level of Lopinavir?
61. Lopinavir 100mg /ritonavir 400 mg
(continue…)
- Advantages
- potent antiretroviral activity
- co-formulated as Kaletra(R)
- once daily dosing is an option for treatment-naive patients
- no food restriction with oral tablet formulation
- Disadvantages
- GI intolerance (once daily associated with a
higher incidence compared with twice daily)
- hyperlipidemia
- possibly lower drug exposure in pregnant women
• Saquinavir:
– Available as hard gel capsule or soft. However, this drug has
very short t1/2 and low bioavailability (12% and decreases of
taken with fatty meal); therefore, it is combined with ritonavir.
Why?
– Side Effects: Headache and nausea.
62. MCQs
• Which of the following are protease inhibitors:
1) Nelfinavir
2) Saquinavir
3) Abacavir
4) Ritonavir
5) Tenofovir
Nevirapine is a
1) Protease inhibitor
2) NRTI
3) NNRTI
4) Fusion inhibitor
Regarding Ritonavir in AIDS
1) should not be used alone
2) contraindicated in renal failure
3) GIT symptoms can be seen
4) may decrease the level of warfarin
63. Regimens for RX of AIDS patients.
•
Highly Active Antiretriviral Therapy (HAART)
(Figure 38-17) consists of:
–
Two NRTIs (why) plus:
One NNRTI or protease inhibitor
However, now aday most regimens use protease inhibitors
What should be done if some one working in the medical
field is exposed accidentally to AIV virus?
How to decrease the development of mutation to HIV
medications?
1) Drugs combination
2) Adherence to medication (missing 6 doses/year)
64. Regimens
- Preferred: (One NNRTIs Plus Two NRTIs)
- Efavirenz (NNRTI) plus (lamivudine or emtricitabine)
Plus (zidovudine or tenofovir (NRTI)) (except in first
trimester of pregnancy or women with high
pregnancy potential)
- Alternative:
- Efavirenz plus (lamivudine or emtricitabine) plus
(abacavir or didanosine or stavudine*) (except in
first trimester of pregnancy or women with high
pregnancy potential)
- Alternative:
- Nevirapine**(NNRTI) plus (lamivudine or emtricitabine)
plus (didanosine or zidovudine or stavudine* or
abacavir or tenofovir)
- * Stavudine has higher incidence of lipoatrophy,
hyperlipidemia, and mitochondrial toxicities than
other NRTIs
65. •
Protease Inhibitor-based
Regimens (2 NRTI plus
prorease inhibitor)
- Prefered
- Indinavir/ritonavir (Kaletral) * plus
(lamivudine or
emtricitabine) plus (zidovudine or
stavudine** or
abacavir or tenofovir or didanosine)
- Alternative:
- Lopinavir/ritonavir plus (lamivudine or
emtricitabine) plus (stavudine** or
abacavir or
tenofovir or didanosine)
•
However, there are too many protocols for
this type of treatment
66. 3) Viral Fusion Inhibitor):
Enfuvirtide
MOA: Block entry into the cell.
Use: not orally but SC for resistance HIV-1 patients.
Regimens for RX of AIDS patients (HAART) (see Fig. 38-
17).
67.
68. • IV. Antihepatitis Agents:
• Like in AIDS, they are suppressive rather than
curative. Among many hepatitis viruses, HBV
and HCV are the most common cause of chronic
hepatitis, cirrhosis, and HCC.
• Drugs for Hepatitis B (see Table )
– Lamivudine:
– MOA: inhibit HBV DNA polymerase and HIV reverse
transcriptase, resulting in chain termination.
• This safest NRTI antiretroviral drug, shows prolonged
intracellular t1/2 in HBV cell lines (17-19 Hr), than in HIV-
infected cell line. So What?.
Effectiveness:
Achieves almost universal HBV DNA suppression, with
decrease in viral replication; and decrease progression to
liver fibrosis.
Response is more rapid than using interferon alone.
69. • Resisitance:
– 20 % can occur after 8-9 months of therapy.
– What is the evidence of resistance?
• 2. Aldefovir:
– This nucleotide (NRTIs) analog is also HBV
infection especially in lamivudine resistance
cases.
– Is there any cross resistance between lamivudine and Aldefovir?
– Side effects:
• Eliminated by glomerular fil.and tubular
secretion, thus it is nephrotoxic.
• Lactic acidosis and hepatomegaly with
steotosis may occur.
70. • 3. Interferon Alfa:
– Endogenous glycoprotein or cytokine that
produced in human leukocytes and exert anitviral,
immunomodulatory and antiproliferative
activities.
Commercially available as:
• Interferon alfa-2b: Licensed for Rx of HBV and
acute hepatitis C.
• Interferon alfa-2a: can be used for HCV (Either
alone or better with oral Ribaverin (quanosine
analog).
Note: Both types can be used for HCV
MOA:
Unclear but may be via the induction of host
cell enzymes that inhibit viral RNA translation
and thus degradation of viral mRNA and tRNA.
71.
72. • PK of interferons:
– Both types could be administered either
S.C or I.M. with short t1/2.(4-7 hrs)
– Filtered unchanged in the glomeruli with
protolytic degradation in the tubule.
– What are the differences between interferon
and pegelated interferon Alfa?
1) Strucure: Peg Interferon alfa-2a and 2b
represent the corresponding interferons with
branched polyethylene moiety is attached by
covalent bind. Thus,
2) Peg has longer t1/2 as compared to normal
interferon. (80 Hr vs 5.1 for alfa-2b) and
increase in renal impairment.
3) Efficacy is superior to non-pegelated
interferon.
73. Other Uses of Interferon:
1) Cancers such as hairy-cell leukemia and Kaposi
sarcoma related to AIDS.
2) Multiple Sclerosis
3) topically for genital warts.
4) prevent dissemination of herpes zoster in cancer
patients or immunocompromised patients
5) Multiple myeloma
Side Effects of interferons:
-Since they are endogenous types of proteins, they may
produce Flu-like symptoms within 6 hr in more than 30%, with
N/V and anorexia; fatigue; rash; alopecia.
- Thrombocytopenia: granulocytopenia and elevation in
aminotransferase level mainly in responders. Induction of
autoantibodies.
- Mental depression and Neurotoxicity (somnolence)
Contraindications:
Psychosis; neutropenia; thrombocytopenia; dermatomyositis
(why).; organ transplanted patients.
74. Ribavirin:
Guanosine analog requires
phosporylation; and inhibits the replication
of wide range of DNA and RNA viruses,
including HCV; HIV; influenza A & B and
respiratory syncytial virus (RSV).
Uses:
Orally: together with interferons for HCV.
Inhaled: For (RSV).
76. • V. Antiviral Used for Respiratory Tract Infections:
1) Inhibitors of viral coating (e,g: Amantadine* and
Rimantadine:
MOA: will Inhibit uncoating of viral RNA of influenza to the
infected host cell, via blocking the viral membrane matrix M2
protein, thus it inhibits the replication of viral RNA.
Note: M2 protein only present in Influenza A? So What?
PK:
Amantadine eliminated unchanged in kidney, while rimantadine
is metabolized in the liver. Both drugs can pass BBB and
available in Tablet forms.
Which one is preferred in a patient with renal failure?
Uses:
For prophylactic and treatment of Influenza A
(Influenza B has different protein in the membrane).
Side Effects:
CNS: Nervousness, difficulty in concentration, lightheadness
GIT:
* Note: Amantadine is also used for management of Parkinson
disease.
77. • 2. Neuraminidase Inhibitors:
What is neuraminidase?
Viruses that cause infuenza like orthomyxovirus
contain the neuraminidase; which can be selectively
inhibited by Zanamavir and Oseltamivir.
MOA:
- Via inhibition of neuraminidase these drugs inhibit
the release of new virions (Influenza viruses employ
specific neuroaminidase that is inserted into the host
cell membrane for the purpose of releasing newly
formed virions. Thus virions accumulate at the
internal infected cell surface. .
- Active against both Influenza A and B.
What is the difference between Amantadine and
Zanamavir?
What are the differences between Zanamavir
(Inhaled) and Oseltamivir (Oral)?
Why Zanamavir should not be given for patients with
78. • 4. Palivizumab:
– Huminized monoclonal antibody directed
against the F glycoprotein on the surface of
RSV
– Uses: only for prevention of high- risk infants